FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Guide on Submitting Continuous Glucose Monitoring Data

FDA posts new technical guidance document outlining how sponsors should submit continuous glucose monitoring data collected during clinical trials for...

latest-news-card-1
Medical Devices

Boston Scientific Device Correction on Certain Pacemakers

Boston Scientific begins a Class 1 recall (device correction) involving certain pacemakers and cardiac resynchronization therapy pacemakers following ...

latest-news-card-1
Animal Drugs

White House Reportedly Moves to Oust Commissioner Makary

Several media outlets report that President Trump has signed off on a plan to remove FDA commissioner Marty Makary from his post.

latest-news-card-1
Biologics

Partner Therapeutics Wins Approval for Bile Duct Cancer Therapy

FDA approves a Partner Therapeutics BLA for Bizengri (zenocutuzumab-zbco) for adults with advanced, unresectable or metastatic cholangiocarcinoma harb...

latest-news-card-1
Animal Drugs

Atara says FDA outlined potential path for Cell Therapy Resubmission

Atara Biotherapeutics says it and partner Pierre Fabre Pharmaceuticals have received feedback from FDA outlining a potential path toward resubmitting ...

latest-news-card-1
Human Drugs

Postapproval Pregnancy Safety Studies Guidance Available

FDA releases a new guidance outlining how drugmakers should design and conduct postapproval studies evaluating the safety of drugs and biologics used ...

latest-news-card-1
Biologics

CBER Acting Head Highlights Regulatory Flexibility, AI and Rare Disease Priorities

CBER acting director Katherine Szarama discusses an expansive vision for the biologics center during remarks at the Food and Drug Law Institutes annua...

latest-news-card-1
Marketing

Advertising Experts Critique FDAs Increasing Enforcement

Pharmaceutical advertising experts react to FDAs dramatically altered enforcement approach toward prescription drug promotion since last fall.

latest-news-card-1
Human Drugs

Sanofi Seeks Removal of Tzield From FDA Priority Review Program

Sanofi asks FDA to remove its Type 1 diabetes therapy Tzield from the agencys National Priority Voucher review program following an internal disagreem...

latest-news-card-1
Human Drugs

Brookings Economist Backs FDA Biosimilar Draft Guide

A Brookings Institution health economist voices support for FDAs revisions to a guidance on questions and answers about biosimilar development and the...